EP4153193A4 - Compositions d'ions cuivre et méthodes de traitement d'états provoqués par le coronavirus et la grippe - Google Patents

Compositions d'ions cuivre et méthodes de traitement d'états provoqués par le coronavirus et la grippe Download PDF

Info

Publication number
EP4153193A4
EP4153193A4 EP21807576.0A EP21807576A EP4153193A4 EP 4153193 A4 EP4153193 A4 EP 4153193A4 EP 21807576 A EP21807576 A EP 21807576A EP 4153193 A4 EP4153193 A4 EP 4153193A4
Authority
EP
European Patent Office
Prior art keywords
coronavirus
influenza
treatment
methods
copper ion
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP21807576.0A
Other languages
German (de)
English (en)
Other versions
EP4153193A1 (fr
Inventor
Chunlim Abbott
Dominic C. Abbott
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CDA Res Group Inc
CDA Research Group Inc
Original Assignee
CDA Res Group Inc
CDA Research Group Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US16/881,937 external-priority patent/US11000545B2/en
Application filed by CDA Res Group Inc, CDA Research Group Inc filed Critical CDA Res Group Inc
Publication of EP4153193A1 publication Critical patent/EP4153193A1/fr
Publication of EP4153193A4 publication Critical patent/EP4153193A4/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/34—Copper; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0046—Ear
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
EP21807576.0A 2020-05-22 2021-03-29 Compositions d'ions cuivre et méthodes de traitement d'états provoqués par le coronavirus et la grippe Pending EP4153193A4 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16/881,937 US11000545B2 (en) 2013-03-15 2020-05-22 Copper ion compositions and methods of treatment for conditions caused by coronavirus and influenza
PCT/US2021/024555 WO2021236231A1 (fr) 2020-05-22 2021-03-29 Compositions d'ions cuivre et méthodes de traitement d'états provoqués par le coronavirus et la grippe

Publications (2)

Publication Number Publication Date
EP4153193A1 EP4153193A1 (fr) 2023-03-29
EP4153193A4 true EP4153193A4 (fr) 2024-02-28

Family

ID=78708069

Family Applications (1)

Application Number Title Priority Date Filing Date
EP21807576.0A Pending EP4153193A4 (fr) 2020-05-22 2021-03-29 Compositions d'ions cuivre et méthodes de traitement d'états provoqués par le coronavirus et la grippe

Country Status (6)

Country Link
EP (1) EP4153193A4 (fr)
JP (1) JP2023526867A (fr)
KR (1) KR20230038422A (fr)
AU (1) AU2021274625A1 (fr)
CA (1) CA3184333A1 (fr)
WO (1) WO2021236231A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10398733B2 (en) 2013-03-15 2019-09-03 Cda Research Group, Inc. Topical copper ion treatments and methods of treatment using topical copper ion treatments in the dermatological areas of the body
US11318089B2 (en) 2013-03-15 2022-05-03 Cda Research Group, Inc. Topical copper ion treatments and methods of making topical copper ion treatments for use in various anatomical areas of the body
US11000545B2 (en) 2013-03-15 2021-05-11 Cda Research Group, Inc. Copper ion compositions and methods of treatment for conditions caused by coronavirus and influenza
US11193184B2 (en) 2019-02-22 2021-12-07 Cda Research Group, Inc. System for use in producing a metal ion suspension and process of using same

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140271495A1 (en) * 2013-03-15 2014-09-18 Chun Lim Abbott Topical Copper Ion Treatments and Methods of Treatment Using Topical Copper Ion Treatments in the Oral-Respiratory-Otic Areas of the Body
WO2021222230A1 (fr) * 2020-04-28 2021-11-04 Oyster Point Pharma, Inc. Administration locale d'agonistes du récepteur nicotinique de l'acétylcholine pour l'inhibition d'infections à coronavirus

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0602325D0 (en) * 2006-02-06 2006-03-15 Remedy Res Ltd Virucidal compositions and uses
US20070243263A1 (en) * 2006-04-14 2007-10-18 Agion Technologies, Inc. Antiviral Methods
EP2786760B1 (fr) * 2008-09-03 2019-01-16 NBC Meshtec, Inc. Agents antiviraux
US11083750B2 (en) * 2013-03-15 2021-08-10 Cda Research Group, Inc. Methods of treatment using topical copper ion formulations
US11000545B2 (en) * 2013-03-15 2021-05-11 Cda Research Group, Inc. Copper ion compositions and methods of treatment for conditions caused by coronavirus and influenza

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140271495A1 (en) * 2013-03-15 2014-09-18 Chun Lim Abbott Topical Copper Ion Treatments and Methods of Treatment Using Topical Copper Ion Treatments in the Oral-Respiratory-Otic Areas of the Body
WO2021222230A1 (fr) * 2020-04-28 2021-11-04 Oyster Point Pharma, Inc. Administration locale d'agonistes du récepteur nicotinique de l'acétylcholine pour l'inhibition d'infections à coronavirus

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
RAHA SYAMAL ET AL: "Is copper beneficial for COVID-19 patients?", MEDICAL HYPOTHESES, EDEN PRESS, PENRITH, US, vol. 142, 5 May 2020 (2020-05-05), XP086252223, ISSN: 0306-9877, [retrieved on 20200505], DOI: 10.1016/J.MEHY.2020.109814 *
See also references of WO2021236231A1 *

Also Published As

Publication number Publication date
CA3184333A1 (fr) 2021-11-25
WO2021236231A1 (fr) 2021-11-25
KR20230038422A (ko) 2023-03-20
AU2021274625A1 (en) 2023-01-05
EP4153193A1 (fr) 2023-03-29
JP2023526867A (ja) 2023-06-23

Similar Documents

Publication Publication Date Title
EP4153193A4 (fr) Compositions d'ions cuivre et méthodes de traitement d'états provoqués par le coronavirus et la grippe
EP4136254A4 (fr) Compositions ciblant l'ace2 et procédés de traitement de la covid-19
EP4100053A4 (fr) Compositions et méthodes de détection de coronavirus
EP4149452A4 (fr) Polythérapie de troubles hépatiques
EP4096675A4 (fr) Compositions et procédés de traitement de la covid longue
EP4149453A4 (fr) Polythérapies contre des troubles hépatiques
EP4126066A4 (fr) Compositions et procédés de traitement d'une dystrophie musculaire
EP4110369A4 (fr) Méthodes de traitement et compositions associées
EP4100029A4 (fr) Compositions et procédés pour les utiliser pour le traitement de la mammite
EP4051260A4 (fr) Méthodes et compositions de traitement du cancer
EP3801590A4 (fr) Compositions et procédés de traitement du psoriasis
EP3911358A4 (fr) Méthodes et compositions de traitement du cancer
IL308180A (en) Preparations and methods for use in corona virus and flu
EP4153609A4 (fr) Compositions et méthodes de prévention d'infection à coronavirus
EP4132503A4 (fr) Méthode de traitement d'une infection à coronavirus
EP4126038A4 (fr) Compositions de vaccin pour le traitement du coronavirus
EP4099997A4 (fr) Méthodes et compositions pour le traitement de maladies
EP4175978A4 (fr) Compositions et méthodes pour traiter des maladies médiées par crp
EP3976115A4 (fr) Compositions et méthodes de traitement de l'hémochromatose
EP4114864A4 (fr) Compositions et méthodes de traitement du cancer
EP3946420A4 (fr) Procédés et compositions pour le traitement d'une infection à coronavirus et coagulopathie associée
EP4103192A4 (fr) Compositions et méthodes de traitement d'infections à coronavirus
EP4021410A4 (fr) Compositions d'oxytocine pour le traitement de l'acouphène
EP4120863A4 (fr) Procédé de traitement d'une infection à coronavirus
EP4003388A4 (fr) Composition et procédé pour améliorer la performance tissulaire

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

TPAC Observations filed by third parties

Free format text: ORIGINAL CODE: EPIDOSNTIPA

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20221121

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230509

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20240131

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 31/14 20060101ALI20240125BHEP

Ipc: A61K 47/12 20060101ALI20240125BHEP

Ipc: A61K 9/10 20060101ALI20240125BHEP

Ipc: A61K 9/00 20060101ALI20240125BHEP

Ipc: A61K 9/06 20060101ALI20240125BHEP

Ipc: A61L 26/00 20060101ALI20240125BHEP

Ipc: A61K 33/34 20060101AFI20240125BHEP